Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Lantheus Holdings Inc

0L8
Current price
95.78 EUR +1.46 EUR (+1.55%)
Last closed 105.55 USD
ISIN US5165441032
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange Frankfurt Exchange
Capitalization 7 328 399 872 USD
Yield for 12 month +67.72 %
1Y
3Y
5Y
10Y
15Y
0L8
21.11.2021 - 28.11.2021

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts. Address: 201 Burlington Road, Bedford, MA, United States, 01730

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

144.55 USD

P/E ratio

17.3602

Dividend Yield

Current Year

+1 296 429 000 USD

Last Year

+935 061 000 USD

Current Quarter

+394 091 000 USD

Last Quarter

+369 975 000 USD

Current Year

+709 543 000 USD

Last Year

+581 703 000 USD

Current Quarter

+255 774 000 USD

Last Quarter

+251 778 000 USD

Key Figures 0L8

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 516 288 992 USD
Operating Margin TTM 26.07 %
PE Ratio 17.3602
Return On Assets TTM 17.41 %
PEG Ratio 0.61
Return On Equity TTM 54.26 %
Wall Street Target Price 144.55 USD
Revenue TTM 1 438 011 008 USD
Book Value 14.79 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 22.5 %
Dividend Yield
Gross Profit TTM 581 703 000 USD
Earnings per share 6.08 USD
Diluted Eps TTM 6.08 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY -33.8 %
Profit Margin 29.8 %

Dividend Analytics 0L8

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History 0L8

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation 0L8

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 17.3602
Forward PE 1.4186
Enterprise Value Revenue 4.9997
Price Sales TTM 5.0962
Enterprise Value EBITDA 11.3445
Price Book MRQ 7.1379

Financials 0L8

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators 0L8

For 52 weeks

50.2 USD 126.89 USD
50 Day MA 104.36 USD
Shares Short Prior Month 3 743 148
200 Day MA 76.17 USD
Short Ratio 4.39
Shares Short 4 252 455
Short Percent 8.08 %